Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood.

Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK.

Drug Deliv. 2013 Aug;20(6):247-51. doi: 10.3109/10717544.2013.822945.

PMID:
23869788
2.

Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain.

Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK.

J Psychiatr Res. 2012 Sep;46(9):1133-8. doi: 10.1016/j.jpsychires.2012.05.014. Epub 2012 Jun 30.

PMID:
22749490
3.

Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug.

Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK, Bhatnagar A.

Int J Pharm. 2014 Aug 15;470(1-2):99-106. doi: 10.1016/j.ijpharm.2014.05.004. Epub 2014 May 6.

PMID:
24810241
4.
5.

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M.

Int J Nanomedicine. 2011;6:363-71. doi: 10.2147/IJN.S15881. Epub 2011 Feb 15.

6.

Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.

Gabal YM, Kamel AO, Sammour OA, Elshafeey AH.

Int J Pharm. 2014 Oct 1;473(1-2):442-57. doi: 10.1016/j.ijpharm.2014.07.025. Epub 2014 Jul 22.

PMID:
25062866
7.

Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen.

Han F, Li S, Yin R, Shi X, Jia Q.

Drug Dev Ind Pharm. 2008 Apr;34(4):453-8. doi: 10.1080/03639040701833708 .

PMID:
18401788
8.

Optimization of artemether-loaded NLC for intranasal delivery using central composite design.

Jain K, Sood S, Gowthamarajan K.

Drug Deliv. 2015;22(7):940-54. doi: 10.3109/10717544.2014.885999. Epub 2014 Feb 10.

PMID:
24512368
9.

Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation.

Han F, Yin R, Che X, Yuan J, Cui Y, Yin H, Li S.

Int J Pharm. 2012 Dec 15;439(1-2):349-57. doi: 10.1016/j.ijpharm.2012.08.040. Epub 2012 Sep 15.

PMID:
22989987
10.

Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia.

Sharma P, Dube B, Sawant K.

J Nanosci Nanotechnol. 2011 Aug;11(8):6676-82.

PMID:
22103067
11.

Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats.

Khan S, Patil K, Bobade N, Yeole P, Gaikwad R.

J Drug Target. 2010 Apr;18(3):223-34. doi: 10.3109/10611860903386938.

PMID:
20030503
12.

Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression.

Haque S, Md S, Sahni JK, Ali J, Baboota S.

J Psychiatr Res. 2014 Jan;48(1):1-12. doi: 10.1016/j.jpsychires.2013.10.011. Epub 2013 Oct 23.

PMID:
24231512
13.

Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique.

Chen S, Liu W, Wan J, Cheng X, Gu C, Zhou H, Chen S, Zhao X, Tang Y, Yang X.

Drug Dev Ind Pharm. 2013 Jan;39(1):20-8. doi: 10.3109/03639045.2011.650648. Epub 2012 Nov 2.

PMID:
23116283
14.

The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.

Li F, Weng Y, Wang L, He H, Yang J, Tang X.

Int J Pharm. 2010 Jun 30;393(1-2):203-11. doi: 10.1016/j.ijpharm.2010.04.005. Epub 2010 Apr 10.

PMID:
20385221
15.

Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design.

Patel K, Padhye S, Nagarsenker M.

AAPS PharmSciTech. 2012 Mar;13(1):125-33. doi: 10.1208/s12249-011-9727-6. Epub 2011 Dec 14.

16.

Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications.

Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O.

Int J Nanomedicine. 2012;7:1841-50. doi: 10.2147/IJN.S29710. Epub 2012 Apr 11.

17.

Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats.

Khan S, Patil K, Yeole P, Gaikwad R.

J Pharm Pharmacol. 2009 May;61(5):669-75. doi: 10.1211/jpp/61.05.0017.

PMID:
19406007
18.

Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats.

Furubayashi T, Kamaguchi A, Kawaharada K, Masaoka Y, Kataoka M, Yamashita S, Higashi Y, Sakane T.

Biol Pharm Bull. 2007 Mar;30(3):608-11.

19.

Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).

Fang JY, Fang CL, Liu CH, Su YH.

Eur J Pharm Biopharm. 2008 Oct;70(2):633-40. doi: 10.1016/j.ejpb.2008.05.008. Epub 2008 Jun 5.

PMID:
18577447
20.

[Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration].

Tao T, Zhao Y, Yue P, Dong WX, Chen QH.

Yao Xue Xue Bao. 2006 Nov;41(11):1104-10. Chinese.

PMID:
17262956
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk